1. Pink Sheet

What To Expect As IRA Legal Challenges Mount

US Chamber Of Commerce Suit Raises New Arguments

 
• By Jessica Merrill

Second lawsuit filed against the IRA is not brought by an industry insider, which may reduce the focus on the drug pricing elements of the new Medicare program and highlight the free enterprise principles at stake, potentially putting the case on a more popular footing.

judge gavel
A second lawsuit was filed against the IRA • Source: Shutterstock

Just days after Merck & Co., Inc. filed the first lawsuit against the US government over the implementation of a new Medicare drug price negotiation program ordered under the Inflation Reduction Act (IRA), a second lawsuit was filed by the US Chamber of Commerce.

Key Takeaways
  • The US Chamber of Commerce filed a second lawsuit against the IRA.
  • A broad business organization like the chamber could help reframe the political dialogue around...

“I think we expected a lawsuit from the pharmaceutical industry, which is the most directly impacted by the law, but it is interesting to see a lawsuit from the Chamber...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Pink Sheet

MAHA Commission Outlines Enhanced Research On Drug Safety In Children

 
• By Cathy Kelly

Research would include initiatives on reproducing industry-sponsored studies, postmarket surveillance, and studies of long-term neurodevelopmental and metabolic outcomes for commonly prescribed pediatric drugs.

Non-User Fee Dollars Increased In US FDA’s Updated FY 2026 Budget Request

 
• By Derrick Gingery

The budget authority total, which is significantly higher than the amount floated in an April OMB draft document, suggests there may have been successful lobbying to increase FDA funding.

US ‘Most Favored Nation’ Pricing Could be Game Changer for Drug Access In Germany

 
• By Francesca Bruce

In this first in a series of articles looking at the potential impact of the MFN drug pricing policy on European pharmaceutical markets, EUCOPE’s Alexander Natz tells the Pink Sheet why the US policy underscores the importance of confidential net pricing.